Aevi Genomic Medicine, LLC
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$8.7M | −$10.9M | −$11.1M | −$36.6M | −$18.9M | −$17.8M |
| Net income | −$8.7M | −$10.9M | −$11.1M | −$38.0M | −$18.4M | −$17.1M |
| Total assets | $12.3M | $34.8M | $40.6M | $54.3M | $34.3M | $23.1M |
| Total liabilities | $4.3M | $4.1M | $5.6M | $3.9M | $4.6M | $4.7M |
| Equity | $7.9M | $30.6M | $35.0M | $50.4M | $29.7M | $18.4M |
| EPS (diluted) | $-0.15 | $-0.29 | $-0.34 | $-1.45 | $1.00 | $-1.06 |
| Shares out. | 59.3M | 37.1M | 32.9M | 24.8M | 18.7M | 18.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2018- Operating margin
- —
- Net margin
- —
- Return on equity
- −109.8%
- Return on assets
- −70.9%
- Return on capital (ROCE)
- −110.1%
- Liabilities / assets
- 35.4%
- Debt / equity
- 0.55×
- Book value / share
- $0.13
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2018- Altman Z″ (distress)
- -63.90distress
- Accruals / assets
- 146.1%high accruals
- Piotroski F-Score
- 0/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 2 warning● 1 good- Altman Z″ in the distress zone
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Cola Michael FOfficer — Chief Executive Officer | Jun 9, 2020 | Buy | 100,000 | $2.50 |
| Astrazeneca Plc10% owner | Dec 19, 2019 | Buy | 12.9M | — |
| Mcinaw MichaelOfficer — Interim CFO | Feb 3, 2020 | D | 16,107 | — |
| Duncan Barbara GayleDirector | Feb 3, 2020 | D | 59,524 | — |
| Grano Joseph J JrDirector | Feb 3, 2020 | D | 75,683 | — |
| Bauer Eugene ADirector | Feb 3, 2020 | D | 165,715 | — |
| Clemow Alastair JDirector | Feb 3, 2020 | D | 57,536 | — |
| Children'S Hospital Of Philadelphia Foundation10% owner | Feb 3, 2020 | J | 38.9M | — |
| Cola Michael FOfficer — President and CEO | Feb 3, 2020 | D | 2.3M | — |
| Neil Garry ArthurOfficer — Chief Scientific Officer | Feb 3, 2020 | D | 2.2M | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Shareholder voteFeb 3, 2020
- Unregistered equity sale · Regulation FD disclosure · Other material eventDec 23, 2019
- Entered a material agreementDec 10, 2019
- Entered a material agreement · Other material eventDec 5, 2019
- Other material eventNov 22, 2019
- Entered a material agreementNov 20, 2019
- Delisting / listing-standard notice · Other material eventOct 15, 2019
- Entered a material agreementOct 4, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4PRIMARY DOCUMENTJun 11, 2020
- SC 13G/ASCHEDULE 13G/AFeb 14, 2020
- 15-12BFeb 14, 2020
- EFFECTFeb 13, 2020
- EFFECTFeb 13, 2020
- EFFECTFeb 13, 2020
- SC 13G/AAEVI GENOMIC MEDICINE, INC.Feb 12, 2020
- S-8 POSFeb 12, 2020
- S-8 POSFeb 12, 2020
- S-8 POSFeb 12, 2020
- S-8 POSFeb 12, 2020
- S-8 POSFeb 12, 2020
- S-8 POSFeb 12, 2020
- S-8 POSFeb 12, 2020
- POS AMFeb 12, 2020
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.